[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"subclinical-atherosclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:subclinical-atherosclerosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100631745","adipose-visceral-and-epicardial-risk-evaluation-100631745",false,"NCT07504679","Adipose Visceral and Epicardial Risk Evaluation","AVERE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Outpatients attending screening or prevention programs at Fondazione Policlinico Universitario A. Gemelli IRCCS\n* Ability to provide written informed consent\n* Willingness to undergo:\n* Additional blood collection for metabolic and inflammatory biomarker analyses\n* Liver elastography (FibroScan)\n\nExclusion Criteria:\n\n* Documented history of atherosclerotic cardiovascular disease, including myocardial infarction, angina pectoris, coronary angioplasty, coronary artery bypass grafting, peripheral artery disease, lower limb revascularization procedures, ischemic stroke, hemodynamically significant carotid stenosis, carotid endarterectomy or angioplasty, or aortopathy;\n* Known chronic liver disease of other etiology (e.g., viral hepatitis, autoimmune liver disease, hemochromatosis, alcoholic liver disease);\n* Significant alcohol consumption (\\>30 g\u002Fday for men, \\>20 g\u002Fday for women);\n* Chronic systemic inflammatory diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriasis, inflammatory bowel disease, spondyloarthritis, mixed connective tissue disease, etc.);\n* Active chronic infections, including HIV, active hepatitis B or C, untreated latent tuberculosis, or any other diagnosed chronic infection;\n* Active or past malignancy within the last 5 years;\n* Current treatment with systemic anti-inflammatory drugs, immunosuppressants, or corticosteroids at pharmacological doses;\n* Current pregnancy or breastfeeding;\n* Any clinical or psychiatric condition that, in the investigator's judgment, could compromise participation or the validity of collected data.",true,"ALL","18 Years","80 Years",{"count":21,"type":22},400,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this procedure-based interventional study without drugs or devices is to investigate the molecular mechanisms underlying metabolically unfavorable obesity and related clinical phenotypes, in order to identify non-invasive biomarkers capable of early prediction of metabolic syndrome, type 2 diabetes mellitus, MASLD, and cardiovascular disease in adult participants without known cardiovascular or liver disease.\n\nThe main questions it aims to answer are:\n\n* What is the association between epicardial and visceral fat thickness and plasma levels of low-grade inflammatory biomarkers?\n* How do these parameters relate to the presence of metabolic syndrome, type 2 diabetes mellitus, MASLD, and subclinical atherosclerosis?\n\nParticipants will:\n\n* Undergo a comprehensive clinical evaluation, including demographic, anthropometric, and medical history data;\n* Complete non-invasive diagnostic assessments, including 12-lead electrocardiogram, transthoracic echocardiography, liver elastography (FibroScan), and carotid Doppler ultrasound;\n* Provide peripheral venous blood samples for biochemical, cellular, and molecular analyses.",[28],"Subclinical Atherosclerosis","NOT_YET_RECRUITING","2026-03-26",{"date":32,"type":33},"2026-04-01","ACTUAL",{"date":35,"type":22},"2026-05-01",{"date":37,"type":22},"2029-12-31",{"name":39,"class":40},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100624655","guideline-adherence-in-dyslipidemia-with-clinical-decision-support-100624655","NCT07412457","Guideline Adherence in Dyslipidemia With Clinical Decision Support","Assessment of Adherence to Clinical Practice Guidelines in Patients With Dyslipidemia Using a Clinical Decision Support System","Inclusion Criteria:\n\n1. Availability of the required amount of patient data for completion of the questionnaire-based system;\n2. Age 18 years or older;\n3. Signed informed consent to participate in the study.\n\nNon-inclusion criteria:\n\n1. Patients with insufficient data to complete the questionnaire;\n2. Refusal to sign informed consent for participation in the study.\n\n   Exclusion Criteria:\n3. Absence of a consensus opinion on the clinical case among two of the three experts.",{"count":49,"type":22},500,"OBSERVATIONAL","Objective: To validate the performance of the developed clinical decision support system (CDSS) for participants with lipid metabolism disorders based on a decision tree algorithm.\n\nMaterials and Methods: A clinical decision support system for participants with lipid profile abnormalities will be developed using the Orbeon open-source online form creation platform based on current clinical guidelines.\n\nDuring the CDSS pilot implementation, the electronic medical records (EMRs) of 500 participants from the Institute of Personalized Cardiology of the Biomedical Science and Technology Park at Sechenov University will be analyzed.\n\nRetrospective data on prescribed lipid-lowering therapy extracted from the EHR will be compared with the CDSS recommendations. The accuracy of the decisions will be assessed by three independent experts based on digitized clinical and laboratory patient profiles.\n\nThe primary endpoint of the study will be to determine the accuracy of the system.\n\nResults: This study will result in the development (creation) and pilot application of the CDSS program in participants with dyslipidemia in real clinical practice.\n\nConclusion: The developed CDSS system for dyslipidemia will significantly reduce the time required for clinical decision-making and help avoid errors in the interpretation of patient data.",[53,54,55,56,28],"Dyslipidemia","Coronary Artery Disease","Atherosclerosis of Major Arteries","Cardiovascular Risk",[58,59,60,61],"dyslipidemia","atherosclerosis","revascularization","cardiovascular risk","2026-02-22",{"date":64,"type":33},"2026-02-24",{"date":32,"type":22},{"date":67,"type":22},"2027-09-30",{"name":69,"class":40},"I.M. Sechenov First Moscow State Medical University",1]